发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Establishing a national standard to achieve better outcomes for people living with chronic obstructive pulmonary disease. 建立国家标准，以改善慢性阻塞性肺病患者的预后。
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.053
Lee Fong, Maria B Sukkar, Rana Ahmed, Alice Bhasale
{"title":"Establishing a national standard to achieve better outcomes for people living with chronic obstructive pulmonary disease.","authors":"Lee Fong, Maria B Sukkar, Rana Ahmed, Alice Bhasale","doi":"10.18773/austprescr.2024.053","DOIUrl":"https://doi.org/10.18773/austprescr.2024.053","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"168-170"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid). 急性他克莫司毒性由于同时使用利托那韦（与尼马特利韦作为Paxlovid）。
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.052
Evan Browne, Cameron White, David Darley, Bridin Murnion
{"title":"Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid).","authors":"Evan Browne, Cameron White, David Darley, Bridin Murnion","doi":"10.18773/austprescr.2024.052","DOIUrl":"https://doi.org/10.18773/austprescr.2024.052","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"192-193"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Top 10 drugs 2023-24. 2023- 2024年十大药物。
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.048
{"title":"Top 10 drugs 2023-24.","authors":"","doi":"10.18773/austprescr.2024.048","DOIUrl":"https://doi.org/10.18773/austprescr.2024.048","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"194"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deucravacitinib for plaque psoriasis. Deucravacitinib治疗斑块型银屑病。
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.049
{"title":"Deucravacitinib for plaque psoriasis.","authors":"","doi":"10.18773/austprescr.2024.049","DOIUrl":"https://doi.org/10.18773/austprescr.2024.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"195-196"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and management of antiphospholipid syndrome. 抗磷脂综合征的诊断和治疗。
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.055
Yeri Ahn, Carolyn Hawkins, Eliza Pearson, Paul Kubler
{"title":"Diagnosis and management of antiphospholipid syndrome.","authors":"Yeri Ahn, Carolyn Hawkins, Eliza Pearson, Paul Kubler","doi":"10.18773/austprescr.2024.055","DOIUrl":"10.18773/austprescr.2024.055","url":null,"abstract":"<p><p>Antiphospholipid syndrome is an autoimmune disease characterised by thrombotic and/or obstetric manifestations with persistent antiphospholipid antibodies. Diagnosis involves confirming the persistence of antiphospholipid antibodies in symptomatic patients, using validated classification criteria as a guide. The likelihood of obtaining false-positive or false-negative test results in certain settings, and the lack of standardisation between laboratory methods, are important considerations. Patients who have had thrombotic manifestations require lifelong anticoagulation from the first thrombotic event, typically with warfarin. Patients with a history of thrombotic and/or obstetric manifestations who become pregnant should receive low-molecular-weight heparin and low-dose aspirin during pregnancy and postpartum. Testing asymptomatic people is not recommended, except in the context of systemic lupus erythematosus. Management of asymptomatic people with persistent antiphospholipid antibodies depends on their individual antibody profile and risk factors.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"179-185"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icosapent ethyl for reduction in cardiovascular disease risk in adults with hypertriglyceridaemia. 降低成人高甘油三酯血症患者心血管疾病的风险
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.050
{"title":"Icosapent ethyl for reduction in cardiovascular disease risk in adults with hypertriglyceridaemia.","authors":"","doi":"10.18773/austprescr.2024.050","DOIUrl":"10.18773/austprescr.2024.050","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"197-198"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral health impacts of vaping. 电子烟对口腔健康的影响
IF 3.4
Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.051
Sue-Ching Yeoh
{"title":"Oral health impacts of vaping.","authors":"Sue-Ching Yeoh","doi":"10.18773/austprescr.2024.051","DOIUrl":"https://doi.org/10.18773/austprescr.2024.051","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"177-178"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing medicine shortages. 管理药品短缺。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.045
Tom Simpson, Jerry Yik
{"title":"Managing medicine shortages.","authors":"Tom Simpson, Jerry Yik","doi":"10.18773/austprescr.2024.045","DOIUrl":"https://doi.org/10.18773/austprescr.2024.045","url":null,"abstract":"<p><p>Medicine shortages are increasingly common and disruptive to the optimal delivery of health care. They are caused by a variety of factors, including manufacturing and supply-chain issues, regulatory and trade issues, and fluctuations in demand. Prescribers and pharmacists in Australia can manage a shortage by switching to another brand, strength or dosage form of the same medicine, switching to a different registered medicine, or accessing an unregistered medicine that has been made available via section 19A of the <i>Therapeutic Goods Act 1989</i> or through the Special Access Scheme. There are a range of resources and tools that can assist clinicians with identifying and managing medicine shortages in Australia. Shortages are managed most effectively when prescribers, pharmacists and nurses work together, in collaboration with patients, to develop, implement and monitor strategies to manage the shortage.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"148-152"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. 为哮喘或慢性阻塞性肺病患者选择吸入器。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.046
Deborah Rigby
{"title":"Inhaler device selection for people with asthma or chronic obstructive pulmonary disease.","authors":"Deborah Rigby","doi":"10.18773/austprescr.2024.046","DOIUrl":"https://doi.org/10.18773/austprescr.2024.046","url":null,"abstract":"<p><p>There are many types of inhaler device, each with its own characteristics, benefits and limitations. Inhaler device selection should be individualised. Assessment of the patient's inspiratory flow, dexterity, coordination and preferences can help guide selection of a device that the patient can and will use effectively. For patients who require multiple inhaled drugs, prescribing combination inhalers and avoiding the use of more than one type of inhaler device can reduce errors in inhaler technique and improve adherence. Inhaler technique and adherence should be regularly reviewed. Environmental impact of inhalers can be reduced by optimising symptom control to minimise the need for short-acting beta<sub>2</sub> agonists, and choosing inhalers with a low carbon footprint.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"140-147"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valediction: Ruth Sutherland. 致辞露丝-萨瑟兰
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.043
{"title":"Valediction: Ruth Sutherland.","authors":"","doi":"10.18773/austprescr.2024.043","DOIUrl":"https://doi.org/10.18773/austprescr.2024.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"156"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信